These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

968 related articles for article (PubMed ID: 29486041)

  • 1. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
    Kaye KS; Bhowmick T; Metallidis S; Bleasdale SC; Sagan OS; Stus V; Vazquez J; Zaitsev V; Bidair M; Chorvat E; Dragoescu PO; Fedosiuk E; Horcajada JP; Murta C; Sarychev Y; Stoev V; Morgan E; Fusaro K; Griffith D; Lomovskaya O; Alexander EL; Loutit J; Dudley MN; Giamarellos-Bourboulis EJ
    JAMA; 2018 Feb; 319(8):788-799. PubMed ID: 29486041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial.
    Kaye KS; Belley A; Barth P; Lahlou O; Knechtle P; Motta P; Velicitat P
    JAMA; 2022 Oct; 328(13):1304-1314. PubMed ID: 36194218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
    Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
    JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections.
    Dhillon S
    Drugs; 2018 Aug; 78(12):1259-1270. PubMed ID: 30128699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae.
    Lee YR; Baker NT
    Eur J Clin Microbiol Infect Dis; 2018 Aug; 37(8):1411-1419. PubMed ID: 29675787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meropenem-vaborbactam for the treatment of complicated urinary tract infections including acute pyelonephritis.
    Wu G; Cheon E
    Expert Opin Pharmacother; 2018 Sep; 19(13):1495-1502. PubMed ID: 30160990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Update on Existing and Emerging Data for Meropenem-Vaborbactam.
    Shoulders BR; Casapao AM; Venugopalan V
    Clin Ther; 2020 Apr; 42(4):692-702. PubMed ID: 32147146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-Daily Plazomicin for Complicated Urinary Tract Infections.
    Wagenlehner FME; Cloutier DJ; Komirenko AS; Cebrik DS; Krause KM; Keepers TR; Connolly LE; Miller LG; Friedland I; Dwyer JP;
    N Engl J Med; 2019 Feb; 380(8):729-740. PubMed ID: 30786187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).
    Wagenlehner FM; Umeh O; Steenbergen J; Yuan G; Darouiche RO
    Lancet; 2015 May; 385(9981):1949-56. PubMed ID: 25931244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial.
    Roilides E; Ashouri N; Bradley JS; Johnson MG; Lonchar J; Su FH; Huntington JA; Popejoy MW; Bensaci M; De Anda C; Rhee EG; Bruno CJ
    Pediatr Infect Dis J; 2023 Apr; 42(4):292-298. PubMed ID: 36689671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
    Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
    Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients?
    McDonald C; Cotta MO; Little PJ; McWhinney B; Ungerer JP; Lipman J; Roberts JA
    Minerva Anestesiol; 2016 Sep; 82(9):957-65. PubMed ID: 27054905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.
    Wunderink RG; Giamarellos-Bourboulis EJ; Rahav G; Mathers AJ; Bassetti M; Vazquez J; Cornely OA; Solomkin J; Bhowmick T; Bishara J; Daikos GL; Felton T; Furst MJL; Kwak EJ; Menichetti F; Oren I; Alexander EL; Griffith D; Lomovskaya O; Loutit J; Zhang S; Dudley MN; Kaye KS
    Infect Dis Ther; 2018 Dec; 7(4):439-455. PubMed ID: 30270406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant
    Petty LA; Henig O; Patel TS; Pogue JM; Kaye KS
    Infect Drug Resist; 2018; 11():1461-1472. PubMed ID: 30254477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
    Wagenlehner FM; Gasink LB; McGovern PC; Moeck G; McLeroth P; Dorr M; Dane A; Henkel T;
    N Engl J Med; 2024 Feb; 390(7):611-622. PubMed ID: 38354140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
    Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C
    Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial.
    Kaye KS; Rice LB; Dane AL; Stus V; Sagan O; Fedosiuk E; Das AF; Skarinsky D; Eckburg PB; Ellis-Grosse EJ
    Clin Infect Dis; 2019 Nov; 69(12):2045-2056. PubMed ID: 30861061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of piperacillin-tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing
    Zhang W; Yan CY; Li SR; Fan TT; Cao SS; Cui B; Li MY; Fan BY; Ji B; Wang L; Cui F; Cui J; Wang L; Guan Y; Wang JW
    Front Cell Infect Microbiol; 2023; 13():1093842. PubMed ID: 37207190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections.
    Naber KG; Savov O; Salmen HC
    Int J Antimicrob Agents; 2002 Feb; 19(2):95-103. PubMed ID: 11850161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.